Skip to main content
. 2021 May 24;71(1):111–120. doi: 10.1007/s00262-021-02966-9

Fig. 2.

Fig. 2

Survival analysis of patients stratified based on PTCH1 status or TMB in the MSKCC cohort a and b OS in patients with and without the PTCH1 mutation in the MSKCC pan-cancer (a) and MSKCC CRC cohort (b). c-f OS curves were plotted for the patients stratified based on the TMB level in the MSKCC cohort. The cutoffs used in this cohort were the top 10% (c), 20% (d), 45% (e), and 50% (f).